Fig. 4
From: Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib
a and b: Progression free survival in sunitinib treated and expression of CD34 and VEGFR2. Patients treated for metastatic renal cell cancer with sunitinib in the first or second line setting (n = 77) comparing CD34 low versus CD34 high and VEGFR2 low versus VEGFR2 high